Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin DiFrancesco

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Therapeutic Drug Monitoring|September 21, 2013
Clinical pharmacology quality assurance program: models for longitudinal analysis of antiretroviral proficiency testing for international laboratoriesRobin DiFrancesco, Susan L Rosenkranz, Charlene R Taylor, et al.
Bioanalysis|June 10, 2016
Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liverAndrew J Ocque, Colleen E Hagler, Robin Difrancesco, et al.
Journal of Clinical Pharmacology|February 28, 2013
Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipientsKathleen M Tornatore, Patcharaporn Sudchada, Kris Attwood, et al.
Pharmacotherapy|March 1, 2006
Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteersDesiree L Tomilo, Patrick F Smith, Abayomi B Ogundele, et al.
Drug and Alcohol Dependence|July 24, 2007
Interaction between buprenorphine and atazanavir or atazanavir/ritonavirElinore F McCance-Katz, David E Moody, Gene D Morse, et al.
Journal of the American Society for Mass Spectrometry|October 2, 2025
Proteoform Characterization of HIV-1 Broadly Neutralizing Antibody PGT 121.414.LS Product Through Middle-Up and Bottom-Up Proteomics for Clinical SupportConnor E Gould, Qing Ma, Raymond Cha, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individualsGene D Morse, Susan Rosenkranz, Michael F Para, et al.
Clinical Pharmacokinetics|January 7, 2005
Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individualsPatrick F Smith, Robert Dicenzo, Alan Forrest, et al.
HIV Clinical Trials|January 25, 2008
The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patientsLisa M Demeter, A Lisa Mukherjee, Robin DiFrancesco, et al.
Therapeutic Drug Monitoring|July 2, 2010
Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trialRobin DiFrancesco, Susan Rosenkranz, A Lisa Mukherjee, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Therapeutic Drug Monitoring|September 21, 2013
Clinical pharmacology quality assurance program: models for longitudinal analysis of antiretroviral proficiency testing for international laboratoriesRobin DiFrancesco, Susan L Rosenkranz, Charlene R Taylor, et al.
Bioanalysis|June 10, 2016
Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liverAndrew J Ocque, Colleen E Hagler, Robin Difrancesco, et al.
Journal of Clinical Pharmacology|February 28, 2013
Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipientsKathleen M Tornatore, Patcharaporn Sudchada, Kris Attwood, et al.
Pharmacotherapy|March 1, 2006
Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteersDesiree L Tomilo, Patrick F Smith, Abayomi B Ogundele, et al.
Drug and Alcohol Dependence|July 24, 2007
Interaction between buprenorphine and atazanavir or atazanavir/ritonavirElinore F McCance-Katz, David E Moody, Gene D Morse, et al.
Journal of the American Society for Mass Spectrometry|October 2, 2025
Proteoform Characterization of HIV-1 Broadly Neutralizing Antibody PGT 121.414.LS Product Through Middle-Up and Bottom-Up Proteomics for Clinical SupportConnor E Gould, Qing Ma, Raymond Cha, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individualsGene D Morse, Susan Rosenkranz, Michael F Para, et al.
Clinical Pharmacokinetics|January 7, 2005
Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individualsPatrick F Smith, Robert Dicenzo, Alan Forrest, et al.
HIV Clinical Trials|January 25, 2008
The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patientsLisa M Demeter, A Lisa Mukherjee, Robin DiFrancesco, et al.
Therapeutic Drug Monitoring|July 2, 2010
Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trialRobin DiFrancesco, Susan Rosenkranz, A Lisa Mukherjee, et al.
Pageof 6